Dogwood Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 21, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Sealbond Ltd filed an amended Schedule 13D on October 21, 2026 regarding its beneficial ownership position in Dogwood Therapeutics, Inc. The filing does not contain specific share counts, percentages, or dollar amounts in the provided text; only the amendment date, filer identity (Sealbond Ltd, Hong Kong-based), and subject company (Dogwood Therapeutics, Georgia-based) are disclosed. The actual amendment details are in the referenced documents but not reproduced in the accessible text extract.
Why this rating
Amendment to ownership disclosure is routine administrative filing. Without specific stake change data, cannot assess materiality. Sealbond's ownership stake relative to $8.1M market cap would need quantification to judge significance.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.